These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26394633)

  • 1. Bivalent rLP2086 Vaccine (Trumenba(®)): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years.
    Shirley M; Dhillon S
    BioDrugs; 2015 Oct; 29(5):353-61. PubMed ID: 26394633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MenB-FHbp Meningococcal Group B Vaccine (Trumenba
    Shirley M; Taha MK
    Drugs; 2018 Feb; 78(2):257-268. PubMed ID: 29380290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains.
    Harris SL; Donald RG; Hawkins JC; Tan C; O'Neill R; McNeil LK; Perez JL; Anderson AS; Jansen KU; Jones TR
    Pediatr Infect Dis J; 2017 Feb; 36(2):216-223. PubMed ID: 27846061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
    Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
    Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
    Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine.
    Senders S; Bhuyan P; Jiang Q; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Ginis J; Perez JL
    Pediatr Infect Dis J; 2016 May; 35(5):548-54. PubMed ID: 26835974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
    Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
    Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine.
    Brendish NJ; Read RC
    Expert Rev Vaccines; 2015 Apr; 14(4):493-503. PubMed ID: 25703792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.
    Nissen MD; Marshall HS; Richmond PC; Jiang Q; Harris SL; Jones TR; Jansen KU; Perez JL
    Pediatr Infect Dis J; 2013 Apr; 32(4):364-71. PubMed ID: 23114369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
    Gandhi A; Balmer P; York LJ
    Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults.
    Ostergaard L; Lucksinger GH; Absalon J; Beeslaar J; Eiden J; Jansen KU; York LJ; Quinn A; Graversen ME; Perez JL
    Vaccine; 2016 Mar; 34(12):1465-71. PubMed ID: 26845739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.
    Seib KL; Scarselli M; Comanducci M; Toneatto D; Masignani V
    Expert Rev Vaccines; 2015 Jun; 14(6):841-59. PubMed ID: 25704037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.
    Marshall HS; Richmond PC; Nissen MD; Wouters A; Baber J; Jiang Q; Anderson AS; Jones TR; Harris SL; Jansen KU; Perez JL
    Vaccine; 2013 Mar; 31(12):1569-75. PubMed ID: 23352429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
    Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL
    Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
    Vesikari T; Østergaard L; Diez-Domingo J; Wysocki J; Flodmark CE; Beeslaar J; Eiden J; Jiang Q; Jansen KU; Jones TR; Harris SL; O'Neill RE; York LJ; Crowther G; Perez JL
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):152-60. PubMed ID: 26407272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
    Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL
    Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults.
    Sheldon EA; Schwartz H; Jiang Q; Giardina PC; Perez JL
    Hum Vaccin Immunother; 2012 Jul; 8(7):888-95. PubMed ID: 22832260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.